ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcome measures and systemic sclerosis"

  • Abstract Number: 1876 • 2018 ACR/ARHP Annual Meeting

    Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant

    Jennifer Franks1, Viktor Martyanov2, Tammara A. Wood2, Leslie Crofford3, Lynette Keyes-Elstein4, Daniel E. Furst5, Ellen Goldmuntz6, Maureen D. Mayes7, Peter McSweeney8, Richard Nash8, Keith Sullivan9 and Michael L. Whitfield10, 1Geisel School of Medicine at Dartmouth, Hanover, NH, 2Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 4Rho, Inc, Chapel Hill, NC, 5University of California Los Angeles, Los Angeles, CA, 6NIAID, NIH, Bethesda, MD, 7Rheumatology, University of Texas McGovern Medical School, Houston, TX, 8Colorado Blood Cancer Institute, Denver, CO, 9Duke University Medical Center, Durham, NC, 10Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH

    Background/Purpose: The SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial (Sullivan K. et al, 2018) demonstrated the clinical benefit of hematopoietic stem cell transplant (HSCT) compared to…
  • Abstract Number: 726 • 2017 ACR/ARHP Annual Meeting

    Performance of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Scleroderma Lung Study-I

    Dinesh Khanna1, Donald P. Tashkin2, Holly Wilhalme2 and Chi-hong Tseng3, 1University of Michigan, Ann Arbor, MI, 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: The CRISS has been proposed as a composite outcome measure for trials in systemic sclerosis1. CRISS is a 2-step process that assigns a probability…
  • Abstract Number: 2662 • 2017 ACR/ARHP Annual Meeting

    The EULAR Systemic Sclerosis Impact of Disease (ScleroID) Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis – Preliminary Results from the Ongoing Validation Study

    Rucsandra Dobrota1, Mike Oliver Becker1, Kim Fligelstone2, Jaap Fransen3, Ann Kennedy4, Yannick Allanore5, Patricia Carreira6, László Czirják7, Christopher Denton8, Roger Hesselstrand9, Gunnel Sandqvist10, Otylia Kowal-Bielecka11, Marco Matucci-Cerinic12, Carina Mihai13, Ana Maria Gheorghiu14, Ulf Müller-Ladner15, MC Vonk16, Turid Heiberg17 and Oliver Distler18, 1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 3Department of Rheumatolgy, Radboud University Medical Center, Nijmegen, Netherlands, 4Federation of European Scleroderma Associations (FESCA), Tournai, Belgium, 5Department of Rheumatology, Cochin Hospital, Paris Descartes University, Paris, France, 6Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 7Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, 8Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, 9Lund University, Lund, Sweden, 10Department of Rheumatology, Lund University Hospital, Lund, Sweden, 11Department of Rheumatology and Internal Medicine, Medical University of Białystok, Białystok, Poland, 12Dept of Medicine/Div of Rheum, University of Florence, Florence, Italy, 13Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 14Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, 15Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, 16Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 17Department of Health and Social Sciences, Oestfold University College, Oslo, Norway, 18Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Patient reported outcome measures (PROM) are acknowledged a key role in clinical trials in systemic sclerosis (SSc). Given the unmet need of a validated,…
  • Abstract Number: 2981 • 2017 ACR/ARHP Annual Meeting

    Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (CRISS) in the Fasscinate Trial

    Dinesh Khanna1, Veronica J. Berrocal2, Christopher Denton3, Angelika Jahreis4, Helen Spotswood5, Celia J. F. Lin4, Jeffrey Siegel6 and Daniel E. Furst7, 1University of Michigan, Ann Arbor, MI, 2Div of Rheumatology, University of Michigan, Ann Arbor, MI, 3Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, 4Genentech, South San Francisco, CA, 5Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, 6Roche Products Ltd., Welwyn Garden City, United Kingdom, 7University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Treatment with Interleukin-6R inhibitor, tocilizumab (TCZ), in early progressive systemic sclerosis (SSc; the faSScinate trial) resulted in consistent, but not statistically significant, improvements in…
  • Abstract Number: 2909 • 2016 ACR/ARHP Annual Meeting

    Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis

    John Pauling1,2, Tracy M. Frech3,4, Michael Hughes5, Jessica K. Gordon6, Robyn T. Domsic7, Francesca Ingegnoli8, Neil J. McHugh1,9, Sindhu R. Johnson10, Marie Hudson11, Francesco Boin12, Voon Ong13, Marco Matucci Cerinic14, Nezam Altorok15, Marina Scolnik16, Mandana Nikpour17, Ankoor Shah18, Janet E. Pope19, Dinesh Khanna20 and Ariane L. Herrick21, 1Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 2Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, 4Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, 5Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine - Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 8Department of Rheumatology, Istituto Gaetano Pini, University of Milano, Italy, Milano, Italy, 9Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom, 10Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 11Department of Medicine, McGill University and Jewish General Hospital, Montreal, QC, Canada, 12Rheumatology, University California San Francisco, San Francisco, CA, 13Rheumatology, University College London Medical School, Royal Free Hospital, London, UK, London, United Kingdom, 14Department of Medicine, Division of Rheumatology, University of Florence, Italy, Florence, Italy, 15Rheumatology, University of Toledo Medical Center,, Toledo, OH, 16Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 17Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Australia, 18Rheumatology and Immunology, Duke University Medical Center, Durham, NC, 19Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, 20Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, 21Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose:  The Raynaud’s Condition Score (RCS) diary is a clinician-derived validated patient-reported outcome (PRO) instrument for assessing the frequency, duration and severity of Raynaud's phenomenon…
  • Abstract Number: 415 • 2015 ACR/ARHP Annual Meeting

    Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)

    Ivan Foeldvari1, Gyorgyi Zoltan2, Eileen Baildam3, Ezgi Deniz Batu4, Michael Blakley5, Mustafa Cakan6, Megan Curran7, Antonia Kienast8, Kim Fligelstone9, Dana Nemkova10, Clarissa Pilkington11, Nicolino Ruperto12, Maria Tsinti13, Elena Tsitsami14, Kristina Urbanvica15 and Tamas Constantin16, 1Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, 2Semmelweiss University Budapest, Budapest, Hungary, 3Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 4Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 5Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, 6Pediatric Rheumatology University Childrens Hospital Istanbul, Istanbul, Turkey, 7Pediatric Immunology/Rheum, UCSF, San Francisco, CA, 8Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, 9FESCA - Scleroderma parents organisation, UK, United Kingdom, 10Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 11Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 12Pediatrica II, Instituto Giannina Gaslini, PRINTO, Genoa, Italy, 13Ped rheum univ child hosp athen, Athena, Greece, 14First Department of Pediatrics, Athens University Medical School, Athens, Greece, 15Pediatric Rheumatology, Riga, Latvia, 16Semmelweis University, Budapest, Hungary

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease. We have currently new promising effective medication to treat systemic sclerosis, but no valid outcome measures…
  • Abstract Number: 720 • 2014 ACR/ARHP Annual Meeting

    Measures of Disease Status in Systemic Sclerosis: Systematic Review

    Tien Tay1, Nava Ferdowsi1, Wendy Stevens1, Marie Hudson2, Murray Baron3, Candice Rabusa1, David Prior4, Susanna Proudman5 and Mandana Nikpour6, 1Rheumatology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, 2Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 4Cardiology, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, 5Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, 6Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia

    Background/Purpose : To identify the measures of disease status in systemic sclerosis (SSc) using a systematic review. Methods: A systematic review of Medline (1966-2014), EMBASE…
  • Abstract Number: 737 • 2014 ACR/ARHP Annual Meeting

    Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy

    Graham Dinsdale1, Tonia Moore2, Joanne Manning2, Andrea Murray1, Michael Berks3, Philip Tresadern3, Chris Taylor3, Neil O'Leary4, Chris Roberts4, John Allen5, Marina Anderson6, Maurizio Cutolo7, Roger Hesselstrand8, Kevin Howell9, Paula Pyrkotsch6, Francesca Ravera7, Vanessa Smith10, Alberto Sulli7, Marie Wildt8 and Ariane Herrick1, 1Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom, 3Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, 4Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, United Kingdom, 5Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 6Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 7Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 8Rheumatology, Lund University, Lund, Sweden, 9Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, 10Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

    Background/Purpose Nailfold videocapillaroscopy allows non-invasive assessment of the microcirculation. Image annotation software allows tracking of changes over time; a potential outcome measure for systemic sclerosis…
  • Abstract Number: 2701 • 2014 ACR/ARHP Annual Meeting

    Relevance of the 6-Minute Walking Test in Assessing the Severity and Outcome of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Extensive Interstitial Lung Disease

    Sébastien Sanges1,2,3, David Launay1,2,3, Rennie L. Rhee4, Olivier Sitbon5,6,7, Eric Hachulla2,3,8, Luc Mouthon9, Loïc Guillevin9, Laurence Rottat5,6,7, Pierre Clerson10, Jean-Francois Cordier11, Steven M. Kawut12, Gérald Simonneau5,6,7 and Marc Humbert5,6,7, 1Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, 2EA 2686, Lille, Lille, France, 3Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 4Rheumatology, University of Pennsylvania, Philadelphia, PA, 5Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, Le Kremlin-Bicêtre, France, 6Service de Pneumologie, DHU Thorax Innovation, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, 7INSERM U999, Centre Chirurgical Marie-Lannelongue, LabEx LERMIT, Le Plessis-Robinson, Le Plessis-Robinson, France, 8Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, 9National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 10Orgametrie, Roubaix, France, 11Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, 12Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA

    Background/Purpose In pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc), no study has yet evaluated the correlation between the 6-minute walking test (6MWT) distance…
  • Abstract Number: 1749 • 2013 ACR/ARHP Annual Meeting

    Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction

    Priya Prakash1, Dhaval Kolte1, Sahil Khera1, Jagadish Khanagavi1, Marjan Mujib2, Chandrasekar Palaniswamy3, Farrah Gutwein4, Sachin Sule1, Wilbert S. Aronow3, William H. Frishman3 and Julia Ash4, 1Medicine, New York Medical College, Valhalla, NY, 2Internal Medicine, New York Medical College, Valhalla, NY, 3Cardiology, New York Medical College, Valhalla, NY, 4Rheumatology, New York Medical College, Valhalla, NY

    Background/Purpose: , Systemic Sclerosis (SSc) is associated with an increased risk of cardiovascular diseases, including acute myocardial infarction (AMI). However, whether SSc influences treatment choice and…
  • Abstract Number: 1484 • 2012 ACR/ARHP Annual Meeting

    Investigating Determinants of Subjective and Objective Assessments of Peripheral Vascular Function in Primary Raynaud’s Phenomenon and Systemic Sclerosis

    John D. Pauling1, Jacqueline A. Shipley1, Nigel Harris2 and Neil McHugh2, 1Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: The Raynaud’s condition score (RCS) diary is recommended for use in clinical trials of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We report the…
  • Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting

    Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative

    Lesley Ann Saketkoo1, Reuben Escorpizo2, Kevin J. Keen3, Kim Fligelstone4 and Oliver Distler5, 1LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 2ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, 3Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, 4Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, 5Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology